OUR SCIENCE

Stem cell therapies have the potential to do for chronic diseases what antibiotics did for infectious diseases.

HOW Dezawa MuseCells®
Are extracted

Dezawa MuseCells® naturally exist in very small numbers within adult tissues such as bone marrow, blood, fat, and skin. To make use of them, these rare cells must be carefully identified and purified with specific markers and techniques.

At MCI, we provide licenses for the patented extraction process designed for this purpose. All research findings and clinical results are based on cells produced with this exact method and cannot be assumed to apply to cells prepared in other ways.

Because the process is standardized, it also ensures replicability: when other laboratories use the same licensed approach, the results are consistent.

1. Source Identification:

COMMON SOURCES INCLUDE:

  • Bone marrow 
  • Adipose tissue
  • Skin fibroblasts
  • Peripheral blood 

2. Isolation

3. Culture and expansion

Culture and Expansion: Once isolated, Dezawa MuseCells® are cultured under highly specific, patented conditions designed to promote growth while preserving their natural characteristics. Unlike other stem cells, Dezawa MuseCells® do not require feeder layers, viral reprogramming, or artificial differentiation protocols.

Every ingredient and step in this process matters: even small variations in preparation can alter cell behavior and safety. That is why all published research and clinical results apply only to Dezawa MuseCells® manufactured under MCI’s licensed methods.

All published information utilizes Dezawa MuseCells® that are manufactured in accordance with MCIs patented processes.

HOW MUSE STEMS
Differ from traditional MSC stem cells

Dezawa MuseCells® and their exosomes have been studied primarily in Japan and, in published research, have demonstrated advantages over traditional MSCs and their exosomes — including pluripotency, stress resistance, and a favorable safety profile. These findings apply only to cells produced under Muse Cell Innovations®–licensed methods; products manufactured differently are not supported by this research.

Dezawa Diamond IV®

Traditional MSCs

Differentiable cell types

Most cell types in the body
Osteocytes, chondrocytes, adipocytes

Differentiation ability in vivo

Yes
Very low rate, if any

Tumorigenicity

None
None

Immune rejection due to use of donor cells

None
Lesser extent

Immunosuppressant treatment

Not necessary
Case-by-case

Most effective method for delivery to target organ

Intravenous infusion
Local injection

Distribution in the body after intravenous injection

Target (damaged) organ

Delivery rate to target organ after intravenous injection

~15%
Less than 1%, if any

Main functions after homing to target organ:

Replacement of damaged cells by differentiation

Yes
No

Angiogenesis

Yes
No

Vascular protection

Yes
Yes

Anti-inflammatory effect

Yes
Yes

Anti-fibrotic effect

Yes
Yes

Tissue protective effect

Yes
Yes

Survival in target organ

Longer than several years
No

Necessity for gene manipulation

No
No

Request Licensing Information